Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed/Carboplatin/Radiotherapy and Bevacizumab in Unresectable Stage III NSCLC
NCT00402883Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Nov 2006
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Primary endpoint: Time to Progression at 18 months. Started Nov 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00402883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402883.